Smart insulin pens comparison in 2026 centers on a handful of competitive options — Medtronic InPen, Novo Nordisk NovoPen 6 and NovoPen Echo Plus, Sanofi SoloSmart, the Mallya attachable smart cap from Biocorp, and Pendiq from Germany. All automatically log dose amount and time via Bluetooth to a companion app, eliminating manual diaries and supporting insulin-on-board calculations, dose reminders, and CGM-integrated views. InPen is the most established in the U.S. and works with the broadest set of insulins via U-100 cartridges from Humalog, Novolog, and Fiasp pens. NovoPen 6 and Echo Plus are the leading options for Novo Nordisk users. Combined with a CGM, smart pens create a “DIY closed loop precursor” that captures much of the data benefit of a pump at lower cost and without an attached device.
Smart Pens Compared
| Pen | Manufacturer | Compatible Insulins | CGM Integration | Bolus Calculator |
|---|---|---|---|---|
| InPen | Medtronic | Humalog U-100, Novolog, Fiasp (cartridges) | Dexcom G6/G7, Libre | Yes — built in |
| NovoPen 6 | Novo Nordisk | NovoLog, Fiasp, Tresiba (Penfill) | Via mySugr, Glooko | Via partner apps |
| NovoPen Echo Plus | Novo Nordisk | NovoLog, Fiasp, Tresiba (half-unit doses) | Via mySugr, Glooko | Via partner apps |
| SoloSmart | Sanofi | Lantus, Apidra, Toujeo (cartridge or attached) | Via app + Apple Health | Via partner apps |
| Mallya (smart cap) | Biocorp | Various disposable pens depending on size | Via app | Via partner apps |
| Pendiq 2.0 | Pendiq (Germany) | Various cartridges | Via app | Yes |
| SmartPen by Bigfoot Unity | Bigfoot Biomedical (acquired) | Aspart, lispro | Libre integration | Yes |
InPen — The Most Established Option
- Made by Medtronic; the most widely used smart pen in the U.S.
- Takes standard U-100 3 mL insulin cartridges from Humalog, Novolog, and Fiasp pens
- Half-unit dosing increments
- Bluetooth pairs to iOS and Android app
- Built-in bolus calculator using carb ratio, correction factor, and target
- Dose reminders and missed-dose alerts
- Insulin-on-board (IOB) tracking
- Dexcom G6/G7 and FreeStyle Libre integration
- Family/care team sharing
- Battery life: about 1 year, then replace the pen
NovoPen 6 and NovoPen Echo Plus
- Made by Novo Nordisk
- NovoPen 6: full-unit dosing for adults
- NovoPen Echo Plus: half-unit dosing — popular in pediatrics
- Works only with Novo Nordisk Penfill cartridges (NovoLog, Fiasp, Tresiba)
- NFC tap to phone for dose history (no continuous Bluetooth on older NovoPen 6; Echo Plus adds more connectivity)
- Integrates with mySugr, Glooko, and Novo Nordisk’s NovoCare app
- Battery life: about 5 years
- More widely available in Europe than the U.S. but expanding U.S. availability in 2025-2026
SoloSmart and Sanofi Ecosystem
- Sanofi’s newer entrant for users on Lantus, Apidra, or Toujeo
- Pairs with companion app
- Auto-logging, reminders, sharing
- Less established in U.S. clinical practice than InPen as of 2026
Mallya — The Attachable Smart Cap
- Made by Biocorp (France)
- Attaches to existing disposable insulin pens — does not replace the pen
- Available in versions for different pen manufacturers
- Logs each dose; pairs to companion apps
- Reusable across multiple disposable pens
- Lower cost than buying a new smart pen system
Smart Pen + CGM = “DIY Closed Loop Precursor”
- Smart pen captures every dose with timestamp
- CGM captures glucose every minute or 5 minutes
- App integrates the two for pattern analysis
- You still inject manually — but with accurate data behind every decision
- Approaches some of the benefits of a hybrid closed-loop pump at lower hardware cost
- Good fit for adults on MDI who do not want to wear a pump
Smart Pen vs Pump — Practical Comparison
| Factor | Smart Pen + CGM | Hybrid Closed-Loop Pump |
|---|---|---|
| Hardware on body | CGM only | CGM + infusion set/pod |
| Initial cost | $0 to $100 | $3,000 to $7,000 (often insurance) |
| Ongoing cost | Insulin + CGM | Insulin + CGM + supplies |
| Auto basal adjustment | No | Yes |
| Auto correction doses | No | Yes (most systems) |
| Manual decision burden | Higher | Lower |
| Time-in-range improvement | Modest | Larger |
| Hypoglycemia reduction | Modest | Substantial (PLGS + auto) |
| Discreet | Yes | Less so (pod/tubing) |
Pediatric Considerations
- NovoPen Echo Plus’s half-unit dosing is widely used in pediatric T1D
- InPen also supports half units
- Auto-logging helps parents and school nurses share data
- Missed-dose alerts useful for school-age children
- Family sharing in companion apps lets parents monitor remotely
Insulin Compatibility Quick Reference
| Insulin | Compatible Smart Pens |
|---|---|
| Humalog (lispro) U-100 | InPen, Mallya |
| Novolog/NovoLog (aspart) U-100 | InPen, NovoPen 6, Echo Plus, Mallya |
| Fiasp (faster aspart) U-100 | InPen, NovoPen 6, Echo Plus, Mallya |
| Apidra (glulisine) | SoloSmart, Mallya |
| Lantus (glargine) | SoloSmart, Mallya |
| Toujeo (glargine U-300) | SoloSmart, Mallya |
| Tresiba (degludec) | NovoPen 6, Echo Plus, Mallya |
| Basaglar (glargine) | Mallya, InPen (with compatible cartridge) |
Practical Use Tips
- Keep the smart pen charged or replace battery as recommended
- Confirm dose logged to app after each injection
- Use the bolus calculator consistently — manual estimates undermine the value
- Rotate injection sites the same as with traditional pens (see our treatment guides)
- Review data with your clinician quarterly or at telehealth visits
- Set up Apple Health or Google Fit integration to consolidate data
Related Reading
See our broader guides on diabetes treatment, best diabetes apps 2026, and AI in diabetes management.
The Bottom Line
Smart insulin pens in 2026 are a meaningful upgrade over traditional pens for anyone on multiple daily injections — auto-logging eliminates manual diaries, the bolus calculator and IOB tracking approach pump-like decision support, and CGM integration brings everything into one view. InPen remains the most widely used U.S. option and works with the broadest range of insulins. NovoPen 6 and Echo Plus are leading choices for Novo Nordisk users. SoloSmart serves Sanofi users. Mallya offers a low-cost attachable upgrade to existing disposable pens. Combined with a CGM, smart pens create a data-rich self-management setup that approaches some of the benefits of an automated insulin delivery pump at much lower hardware cost and without an additional device on the body — a useful option for adults on MDI who prefer not to wear a pump.
